Figure 3 Regulation of TGF-β1/Smad signalling by microRNAs (miRs) in tissue fibrosis Figure 3 | Regulation of TGF-β1/Smad signalling by microRNAs (miRs)

Slides:

Advertisements

Similar presentations

Tyrosine kinase signalling (review) TGF signalling Notch signalling.

Advertisements

Figure. Schematic illustration on chitotriosidase (CHIT1) regulation of TGF-β pathway. CHIT1 enhances the effect of TGF-β through the induction of TGF-β.

Nat. Rev. Nephrol. doi: /nrneph

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Figure 2 Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis Figure 2 | Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis.

Figure 6 Effects of adiponectin on podocyte function

Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.

Figure 4 Expression of coagulation protease receptors in renal cells

Figure 4 Interactions between adipose, the microbiome and kidney

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Mechanisms of kidney injury in the setting of obesity

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Role of the kidney in glucose homeostasis

Figure 1 Model of mechanosensation through primary cilia

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Monogenic forms of diabetes mellitus

Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.

Figure 7 The efficacy of phosphate-binder therapy

Figure 3 Putative actions of glucagon-like peptide 1 (GLP-1)

Figure 2 Expression of complement activation products in renal samples

Figure 5 Risk factor control in the intensive treatment group

Figure 2 The network of chronic diseases and their mutual influences

Figure 2 Three distinct mechanisms of activation of

Figure 1 The sensory and secretory function of the L cell

Figure 1 The burden of chronic kidney disease (CKD)

Figure 3 Societal costs for the care of patients with chronic kidney disease in the UK Figure 3 | Societal costs for the care of patients with chronic.

Figure 3 Molecular mechanisms of crystal-induced necroinflammation

Figure 1 Overview of canonical TGF-β/Smad signalling in tissue fibrosis Figure 1 | Overview of canonical TGF-β/Smad signalling in tissue fibrosis. Once.

Figure 2 Molecular pathways involved in the regulation of T-cell differentiation and cytokine production Figure 2 | Molecular pathways involved in the.

Figure 1 Acute kidney injury and chronic kidney disease

Figure 4 The gut–kidney axis, inflammation and cardiovascular disease in CKD Figure 4 | The gut–kidney axis, inflammation and cardiovascular disease in.

Figure 4 Model of changes in the serum levels

Figure 2 Roles of mTOR complexes in the kidney

Nat. Rev. Nephrol. doi: /nrneph

Figure 5 Potential roles of phosphate and fibroblast growth factor 23 (FGF-23) in the development of cardiovascular disease in patients with chronic kidney.

Figure 4 Potential therapeutic strategies to inhibit TGF-β1/Smad-induced tissue fibrosis Figure 4 | Potential therapeutic strategies to inhibit TGF-β1/Smad-induced.

Figure 1 mTOR complex biology

Nat. Rev. Neurol. doi: /nrneurol

Figure 6 Schematic of an analysis of a new biopsy

Figure 2 Initiation, amplification and propagation of coagulation

Figure 1 The coagulation system

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Specificity of the various epidermal growth factor (EGF)

Figure 3 Differentiation and functional control of T-cell subsets

Figure 4 The molecular configuration of the CD20 molecule

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Potential mechanisms of PAR activation by thrombin and aPC

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Localization of ErbB receptors and ligands within the nephron

Nat. Rev. Nephrol. doi: /nrneph

Figure 5 The nephron-centric model of renal transplant fibrosis based on the injury-related molecular events observed in biopsy samples in the first year.

Nat. Rev. Nephrol. doi: /nrneph

Figure 4 Mechanisms of leptin function on kidney injury

Figure 3 Serum phosphate level is associated with

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Mechanistic classification of lncRNAs

Nat. Rev. Nephrol. doi: /nrneph

Figure 2 Biologics that target CD4+ T helper (TH)-cell subsets

Figure 4 The complement drug development pipeline

Figure 1 Patient, facility, health-care system and industry factors

Neurogenins induce a network of transcription factors that mediate iNGN neurogenesisA network of transcription factors involved in iNGN neurogenesis was.

Figure 4 The relationship between the time-dependent changes in the expression of immunoglobulin, mast cell, acute kidney injury (AKI), and fibrillar collagen.

Figure 4 Intracellular distribution and

Figure 1 Worldwide distribution of disease burden attributable to environmental risks in 2012 Figure 1 | Worldwide distribution of disease burden attributable.

miR-29 Inhibits Bleomycin-induced Pulmonary Fibrosis in Mice

Figure 2 Signalling downstream of the IL-6 receptor

Chronic Treg reduction results in dermal fibrosis.

Figure 1 Relationships between genetic variants, quantitative traits and diseases Figure 1 | Relationships between genetic variants, quantitative traits.

Presentation transcript:

Figure 3 Regulation of TGF-β1/Smad signalling by microRNAs (miRs) in tissue fibrosis Figure 3 | Regulation of TGF-β1/Smad signalling by microRNAs (miRs) in tissue fibrosis. Numerous miRs have been implicated in the regulation of tissue fibrosis, particularly kidney fibrosis. miRs are grouped as having an antifibrotic effect (purple), profibrotic effect (pink) or both profibrotic and antifibrotic effects (blue). Whether TGF-β1/Smad3 signalling positively or negatively regulates the transcription of these miRs is indicated, and the target genes inhibited by the miRs are shown. Meng, X.-m. et al. (2016) TGF-β: the master regulator of fibrosis Nat. Rev. Nephrol. doi:10.1038/nrneph.2016.48